REG - EKF Diagnostics Hldg - Hematology contracts signed worth EUR 4.65m

EKF Diagnostics HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250826:nRSZ4937Wa&default-theme=true

RNS Number : 4937W  EKF Diagnostics Holdings PLC  26 August 2025

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Hematology contracts signed worth EUR 4.65m

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics
business, announces that it has signed three new contracts in the key organic
growth area of Hematology point-of-care testing, worth approximately €4.65m
(c. £4.03m), to be delivered over the next 12 to 24 months.

 

The contracts, for the supply of hemoglobin analysers and related
consumables, have been secured by EKF's distribution partners in Latin America
and Africa. One contract represents a return to significant sales in Peru,
following a sharp decline in local sales due to geo-political factors within
the country. Another contract marks EKF's first sales into Uganda, as strong
sales growth continues across Africa.

 

The Company successfully increased supply capacity going into H2 2025 to meet
rising demand. With the order book already at record levels and now full for
2025, further investment will be deployed to grow Hemoglobin consumable and
analyser production capacity at the Barleben site by 30% as part of the
five-year strategic development plan for the business.

 

The additional contracts reinforce the Board's confidence in delivering growth
at the revenue and adjusted EBITDA(1) levels for FY 2025 in-line with market
expectations(2). The continued global expansion of EKF's Hematology analyzer
footprint also provides confidence in future growth as these continue to drive
the pull through of consumables.

 

Commenting, Gavin Jones, Chief Executive Officer, said: "As part of our
five-year strategic development plan to support accelerated organic growth, we
identified that Hemoglobin testing was the most significant growth opportunity
within our POC portfolio. We're very pleased to see that allowing our
dedicated POC sales team to focus on core growth products is bearing fruit,
particularly in Hemoglobin POC testing. As we win more and more new contracts
and increase our global analyser footprint, we will see the benefits not just
this year, but also in the years to come as consumable pull-through drives
higher margin revenue growth."

 

 

(1)Earnings before interest, tax, depreciation and amortisation, excluding
exceptional items.

²Management understands consensus revenue and Adjusted EBITDA forecasts for
FY 2025 to be £53.6m and £12.4m respectively.

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Gavin Jones, Chief Executive Officer.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
 Stephen Young, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTSEWFIEEISESA